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[ABSTRACT] 
Objective: Long-term peritoneal dialysis causes peritoneal fibrosis in submesothelial areas. 
However, the mechanism of peritoneal fibrosis is unclear. Epigenetics is the mechanism to 20 
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induce heritable changes without any changes in DNA sequences. Among epigenetic 
modifications, histone acetylation leads to the transcriptional activation of genes. Recent 
studies indicate that histone acetylation is involved in the progression of fibrosis. Therefore, 
we examined the effect of suberoylanilide hydroxamic acid (SAHA), a histone deacetylase 
inhibitor, on the progression of peritoneal fibrosis in mice. 25 
Methods: Peritoneal fibrosis was induced by the injection of chlorhexidine gluconate (CG) 
into the peritoneal cavity of mice every other day for 3 weeks. SAHA, or a dimethylsulfoxide 
and saline vehicle, was administered subcutaneously every day from the start of the CG 
injections for 3 weeks. Morphologic peritoneal changes were assessed by Masson's trichrome 
staining, and fibrosis-associated factors were assessed by immunohistochemistry. 30 
Results: In CG-injected mice, a marked thickening of the submesothelial compact zone was 
observed. In contrast, the administration of SAHA suppressed the progression of 
submesothelial thickening and type III collagen accumulation in CG-injected mice. The 
numbers of fibroblast-specific protein-1–positive cells and xxa-smooth muscle actin–positive 
cells were significantly decreased in the CG + SAHA group compared to that of the CG 35 
group. The level of histone acetylation was reduced in the peritoneum of the CG group, 
whereas it was increased in the CG + SAHA group.  
Conclusions: Our results indicate that SAHA can suppress peritoneal thickening and 
fibrosis in mice through up-regulation of histone acetylation. These results suggest that 
SAHA may have therapeutic potential for treating peritoneal fibrosis. 40 
KEY WORDS: Suberoylanilide hydroxamic acid, SAHA, histone deacetylase inhibitor, 
peritoneal fibrosis, chlorhexidine gluconate.  
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Although peritoneal dialysis (PD) is a beneficial treatment for patients with end-stage renal 
diseases, long-term PD causes morphologic and functional changes in the peritoneum (1). 45 
Characteristic pathologic findings in the peritoneum, related to long-term PD, include marked 
peritoneal fibrosis and massive accumulation of collagen in submesothelial areas (2, 3). In 
particular, some patients with peritoneal fibrosis develop encapsulating peritoneal sclerosis 
(EPS) associated with high mortality, which is one of the most critical complications in PD. 
However, the mechanism underlying peritoneal fibrosis in PD patients remains poorly 50 
understood and no effective therapy is available at present. To investigate the mechanism of 
peritoneal fibrosis and effective therapy, animal models of peritoneal fibrosis are used. 
Among them, chlorhexidine gluconate (CG) is often used to induce peritoneal fibrosis (4). 
This is a reversible model (5), therefore, repeat injections of CG need to be continued during 
the course of the experiment to induce persistent chemical irritation and tissue damage (6). In 55 
fact, following injection of CG, many pathologic findings in the peritoneum of PD patients, 
including increased expression of collagen III, xxa-smooth muscle actin (xxaSMA), 
macrophage infiltration, were also observed in previous studies (4,7). These similarities in 
alterations of the peritoneal membranes between experimental CG models and human PD 
patients strongly suggest that the CG model is a reasonable candidate model to examine the 60 
efficacy of various potential therapeutic reagents for regulating peritoneal sclerosis. 
Epigenetics is defined as the mechanism to induce heritable change in the pattern of gene 
expression without any changes in DNA sequences (8). Epigenetic regulations depend on 
DNA methylation, histone modification, RNA interference, and so on. It has been shown that 
epigenetic modifications are involved in various human diseases, for example, cancer, 65 
hypertension, diabetes, and atherosclerosis (8). Moreover, a recent study has revealed that 
hypermethylation of rat sarcoma (RAS) protein activator like-1 (RASAL1) is associated with 
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the perpetuation of fibroblast activation and fibrogenesis in the kidney, leading to glomerular 
and interstitial fibrosis (9). 
Among epigenetic regulation, global histone acetylation alters chromatin structure and 70 
regulates the dynamics of gene expression. The level of acetylation reflects a balance 
between histone acetyltransferase (HAT) and histone deacetylase (HDAC) protein families 
(10). Recently, it was demonstrated that HDACs are related to the progression of tissue 
fibrosis in multiple organs including kidney, heart and lung (11). A report showed that 
HDAC levels were increased and histone acetylation was decreased in kidneys injured by 75 
unilateral ureteral obstruction (UUO), which is a model of fibrosis (12). In addition, it has 
been reported that HDAC inhibitors (HDACi) are potentially therapeutic for fibrotic 
disorders because they have anti-fibrotic activity. Among HDACi, suberoylanilide 
hydroxamic acid (SAHA) has nonspecific HDAC-inhibition activity, affecting all classes of 
HDACs, and has received approval from the US Food and Drug Administration for treatment 80 
of refractory cutaneous T-cell lymphoma (13). SAHA exhibits relatively low toxicity towards 
normal cells compared to other HDACi (13). It was reported that SAHA attenuated 
mesangial collagen IV deposition in a mouse model of diabetic nephropathy (14). In addition, 
SAHA also attenuated collagen deposition in the ventricle and cell infiltration throughout the 
interstitium; thereby, improving cardiovascular remodeling in deoxycorticosterone acetate-85 
salt hypertensive rats (15). Furthermore, previous reports indicate that inflammation plays an 
important role in the progression of organ fibrosis, and angiogenesis is associated with the 
development of fibrosis (16,17). It has been also reported that SAHA suppressed 
inflammation and angiogenesis (18,19). Therefore, we used SAHA as an HDACi in our 
present study.  90 
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Generally, increased levels of histone acetylation are associated with transcriptional 
activation (20). Some reports indicate that the expression of fibrosis inhibitory factors can be 
increased by promoting histone acetylation (21,22). As the effects of inhibitory factors for 
fibrosis, Yu et al. reported that bone morphogenetic protein 7 (BMP-7) and hepatocyte 
growth factor (HGF) ameliorated high-glucose–induced epithelial-to-mesenchymal transition 95 
(EMT) of peritoneal mesothelial cells (23). Inhibitors of DNA binding/differentiation 2 (Id2), 
which plays a role in inhibiting TGF-xxb–induced EMT in human renal epithelial cells, were 
shown to be upregulated, together with BMP-7, by HDACi (21). 
In the present study, we hypothesized that HDACi could inhibit peritoneal fibrosis by 
promoting histone acetylation, following the increase of a fibrosis inhibitory factor; we 100 
focused on BMP-7. In this study, we investigated first the changes in histone acetylation in 
the CG-induced fibrotic peritoneum of mice. Then, we determined the effects of HDACi on 
fibrotic changes induced by CG.  
Our results raise the possibility that HDACi may be a useful therapeutic agent for attenuating 
the progression of peritoneal fibrosis. 105 
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METHODS 
ANIMAL MODELS 
The experiments described in this study were conducted on 10-week-old male ICR mice 
(Japan SLC Inc., Shizuoka, Japan). They were housed in standard rodent cages in a light- and 110 
temperature-controlled room in the Biomedical Research Center, Center for Frontier Life 
Sciences, Nagasaki University. They had free access to laboratory food and tap water. The 
experimental protocol was inspected by the Animal Care and Use Committee of Nagasaki 
University, and approved by the President of Nagasaki University (Approval number: 
1004050846). 115 
EXPERIMENTAL PROTOCOL 
Peritoneal fibrosis was induced by intraperitoneal injection of 0.1% CG in 15% ethanol 
dissolved in saline, as described previously, but with a slight modification (16,24). Mice 
received injections of 0.1% CG in 15% ethanol dissolved in saline (CG) or 15% ethanol 
dissolved in saline only at a dose of 0.3 mL/body into the peritoneal cavity every other day 120 
for 3 weeks. SAHA (10009929; Cayman Chemicals, MI, USA), which was dissolved in a 
vehicle (dimethylsulfoxide:saline = 1:1), or a vehicle alone, was administered subcutaneously, 
as previously reported (25). SAHA was administered at a dose of 25 mg/kg body weight 
every day for 3 weeks. Mice were assigned to 4 groups: (1) mice injected 15% ethanol 
dissolved in saline intraperitoneally and vehicle subcutaneously (n = 5), defined as the 125 
control group; (2) mice injected 15% ethanol dissolved in saline intraperitoneally and SAHA 
subcutaneously (n = 5), defined as SAHA group; (3) mice injected CG intraperitoneally and 
vehicle subcutaneously (n = 10), defined as CG group; and (4) mice injected CG 
intraperitoneally and SAHA subcutaneously, defined as CG + SAHA group (n = 10). The 
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dose and interval for administration of SAHA were selected on the basis of pilot studies 130 
conducted to determine the effects of different doses on the thickness of the submesothelial 
area. SAHA at a dose of 12.5 mg/kg body weight did not reduce peritoneal thickness 
compared with that in non-treated CG mice. SAHA at doses of 25 or 50 mg/kg body weight 
reduced peritoneal thickness to the same degree. Therefore, we selected 25 mg/kg body 
weight in the present study. No mice were excluded from the study once they were treated. 135 
Mice were sacrificed at day 21 after the first CG injection, and peritoneal tissues were 
dissected out carefully. To avoid direct damage to the peritoneum due to repeated injections, 
CG was injected at the lower part of the peritoneum, whereas the upper portion of the parietal 
peritoneum was used for the examination. The tissues were fixed with 4% paraformaldehyde 
in phosphate-buffered saline (PBS; pH 7.4) immediately after sampling, and were embedded 140 
in paraffin. For morphological examination of the peritoneum, 4-xxmm thick, paraffin-
embedded tissues were stained with Masson’s trichrome staining. 
IMMUNOHISTOCHEMISTRY 
Paraffin-embedded tissue sections were stained immunohistochemically using an indirect 
method (26). The following antibodies were used for immunohistochemistry: (1) rabbit anti-145 
type III collagen antibody diluted 1:400 (LB-1393; LSL Co., Tokyo, Japan); (2) rabbit anti-
human phosphorylated-Smad2/3 antibody diluted 1:50 (sc-11769-R; Santa Cruz 
Biotechnology, Santa Cruz, CA, USA); (3) rabbit anti-human fibroblast-specific protein-1 
(FSP-1) antibody diluted 1:100 (A5114; DAKO, Glostrup, Denmark); (4) mouse anti-human 
xxaSMA antibody diluted 1:50 (A2547; Sigma-Aldrich, St.Louis, US); (5) rat anti-mouse 150 
F4/80 antibody diluted 1:50 (MCA 497; Serotec, Kidlington, UK); and (6) goat anti-mouse 
PECAM/CD31 antibody diluted 1:50 (sc-1506; Santa Cruz Biotechnology). 
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After deparaffinization, the sections were treated with 0.3% H2O2 for 20 min to inactivate 
endogenous peroxidase activity. For the immunohistochemical analysis of phosphorylated-
Smad2/3 and CD31, the sections were treated in a microwave oven (MI-77; Azumaya, Tokyo, 155 
Japan) at 95°C for 5 or 15 min in 10 mmol/L citrate buffer (pH 6.0), before H2O2 treatment 
for antigen retrieval. For the immunohistochemical analysis of type III collagen, FSP-1, 
F4/80 and xxaSMA, the sections were treated with proteinase K (P2308; Sigma, St Louis, 
MO) for 15 min at 37°C, before H2O2 treatment for antigen retrieval. The sections were 
incubated for 30 min with a blocking solution (5% normal goat serum, 5% fetal calf serum, 160 
5% bovine serum albumin (BSA), and 20% normal swine serum in PBS) at room temperature. 
The sections were then exposed to the primary antibody, which was diluted in the blocking 
buffer. For phosphorylated-Smad2/3 and CD31 staining, the sections were stained with the 
avidin–biotin complex by using a Vectastain Elite ABC kit (Vector Laboratories, Burlingame, 
CA, USA) after reacting with the primary antibody overnight at 4°C. For xxaSMA, the 165 
sections were exposed to a complex of anti-xxaSMA antibody and horseradish peroxidase 
(HRP)-conjugated rabbit anti-mouse immunoglobulin antibody (P0161; Dako) diluted 1:50 
for 30 min at room temperature. Then, sections were incubated with the Envision+ System-
HRP Labelled Polymer Anti-Rabbit (K4002, Dako) for 30 min at room temperature. For type 
III collagen, FSP-1 and F4/80, after reacting with the primary antibodies for 1 h or overnight 170 
at room temperature, the sections were incubated with HRP-conjugated swine anti-rabbit 
immunoglobulin antibody (P0399; Dako) or rabbit anti-rat immunoglobulin antibody (P0450; 
Dako), diluted 1:50, for 30 min at room temperature. The reaction sites were visualized by 
treating the sections with H2O2 and 3,3xx’-diaminobenzidine tetrahydrochloride (26). Finally, 
the sections were counterstained with methyl green and mounted. For all specimens, negative 175 
controls were prepared using normal IgG instead of the primary antibody. 
IMMUNOFLUORESCENCE STAINING 
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The following antibodies were used for immunofluorescence staining: (1) rabbit anti-human 
acetyl-histone H3 (Lys9) antibody, diluted 1:100 (#9671; Cell Signaling Technology, 
Danvers, MA, USA), and (2) goat anti-human BMP-7 antibody diluted 1:25 (SC-9305; Santa 180 
Cruz Biotechnology). 
After deparaffinization, the sections were incubated for 30 min or 1 h with a blocking 
solution consisting of 500 xxmg/mL normal goat IgG and 1% BSA in PBS at room 
temperature. The sections were then incubated with the primary antibodies, which were 
diluted in the same blocking solution. The sections were incubated with either Alexa Fluor  185 
dye (Molecular probes, Inc; Eugene, OR, USA) 594-labeled goat anti-rabbit IgG (A11012; 
Invitrogen, Paisley, UK) or Alexa Fluor dye 488-labeled rabbit anti-goat IgG (A11078; 
Invitrogen) for 1 h, stained with 4,6-diamidino-2-phenylindole (DAPI) for 1 min, and 
mounted. The sections were analyzed using a confocal laser scanning microscope (LSM 5 
PASCAL; Carl Zeiss Co., Ltd., Obekochen, Germany), and the images were obtained. 190 
Normal rabbit or goat IgG was used as a negative control. 
MORPHOMETRIC ANALYSIS 
To assess the extent of peritoneal thickening, we used digitized images and image analysis 
software (Lumina vision; MITANI Corporation, Tokyo, Japan). We measured the thickness 
of the submesothelial zone above the abdominal muscle in cross-sections of the abdominal 195 
wall. The diameter of the × 200 magnification is 1 mm. For each sample, 5 such areas were 
selected and type III collagen-positive areas were determined. In each peritoneal sample, the 
numbers of phosphorylated-Smad2/3–positive cells, cells expressing FSP-1, xxaSMA, F4/80 
or BMP-7, CD31–positive vessels and submesothelial cells were counted in 5 fields at × 200 
magnification. 200 
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QUANTITATIVE RT-PCR 
Quantitative real-time RT-PCR was performed as previously described (27). RNA was 
isolated from the peritoneum with 600 xxmL RNA lysis buffer using an RNeasy Mini Kit 
(QIAGEN, Tokyo, Japan). Complementary DNA was reverse-transcribed using a high-205 
capacity reverse transcription kit (Applied Biosystems, Life Technologies Japan Ltd., Tokyo, 
Japan). Approximately 25 ng cDNA was used as a template in reactions with 0.5 xxmM of 
forward and reverse primers and SYBR Green (Applied Biosystems). Reactions were carried 
out using the StepOne Plus Real-Time PCR system, and quantitative comparisons were 
obtained using the xxDxxDCT method (Applied Biosystem). The following primers were 210 
used in reactions: xxb-actin, 5′-CATCCGTAAAGACCTCTATGCCAC-3′ (forward) and 5′-
ATGGAGCCACCATCCACA-3′ (reverse) (28); BMP-7, 5′-
CACTCCCTCCTCAACCCTCGGCA-3′ (forward) and 5′-
TAGAGGCATCATAGGCCAGGTGCCC-3′ (reverse) (29); xxa1 chain of type I collagen 
(COLIxxa1), 5′-TGGTCCTGCCGGTCCTCCTG-3′ (forward) and 5′-215 
ACACATTGGGGGTAGGAACA-3′ (reverse) (30); Fibronectin, 5′-
GAAACGGCCAACTCCGTCAC-3′ (forward) and 5′-TGGGGTGCCAGTGGTCTCTT-3′ 
(reverse) (31); Connective tissue growth factor (CTGF), 5′-
TGCCAGAACGCACACTGAGG-3′ (forward) and 5′-ATTGCCCTCCCCGGTTACAC-3′ 
(reverse) (31). 220 
STATISTICAL ANALYSIS 
Data were expressed as mean ± standard error mean (SEM). Differences among groups were 
examined for statistical significance by using repeated measures analysis of variance 
(Bonferroni/Dunn test). A p value of < 0.05 denoted statistically significant difference. 
225 
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RESULTS  
SAHA PREVENTED THE PERITONEAL FIBROSIS 
Morphological changes were assessed using Masson’s trichrome staining (Figure 1). In the 
normal mice, the peritoneal tissue comprised a peritoneal mesothelial monolayer and an 
exiguity of connective tissues under the mesothelial layer (Figure 1A). In the control group, 230 
the peritoneal tissues were almost normal and without thickening of the submesothelial zone 
(Figure 1B). On the other hand, the peritoneal samples from the mice in the CG group had a 
marked thickening of the submesothelial compact zone and a heavy infiltration of various 
cells at day 21 (Figure 1C). However, subcutaneous injection of SAHA prevented the 
progression of submesothelial thickening and reduced the number of cells in the CG + SAHA 235 
group (Figure 1D). A significant difference between the CG group and the CG + SAHA 
group was seen in the area of the submesothelial compact zone (p < 0.05, Figure 1E). The 
thickening of the peritoneum was not affected following repeated injections of SAHA 
compared with that of the control group (data not shown).  
For the analysis of collagen deposition, we conducted the immunohistochemistry for type III 240 
collagen at day 21. As shown in Figure 2, in the control group, type III collagen expression in 
the submesothelial compact zone was marginal and equivalent to that of normal mice (Figure 
2A). In the CG group, type III collagen was diffusely expressed in the submesothelial 
compact zone, whereas this expression was clearly decreased in the CG + SAHA group 
(Figure 2B, 2C). When we examined the signal for type III collagen quantitatively, the 245 
expression of type III collagen was higher in the CG group than in the control group, but was 
significantly lower in the CG + SAHA group than in the CG group (Figure 2E). 
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The expression of FSP-1, which is a marker of fibroblasts, was examined by 
immunohistochemistry. A few FSP-1–positive cells were in the peritoneum of the control 
group (data not shown). In the CG group, the number of FSP-1–positive cells increased 250 
markedly compared to that in the control group, and the treatment of SAHA inhibited these 
expressions significantly (Figure 3A – 3D). Furthermore, we examined the expression of 
xxaSMA, which is a marker of myofibroblasts, by immunohistochemistry. In the control 
group, a few xxaSMA–positive cells were found in the peritoneum (data not shown). The CG 
group showed a significant increase of xxaSMA–positive cells, and in the CG + SAHA group, 255 
the number of xxaSMA–positive cells was markedly decreased (Figure 3E – 3H). 
 SAHA SUPPRESSED TRANSFORMING GROWTH FACTOR (TGF)-XXB SIGNALING 
We examined TGF-xxb signaling by performing immunohistochemistry for phosphorylated-
Smad2/3, which is known as a mediator of TGF-xxb signaling in regulation of the fibrotic 
response (Figure 4). In the control group, very few phosphorylated-Smad2/3–positive cells 260 
were observed in the peritoneum (data not shown). Treatment with CG significantly 
increased the number of phosphorylated-Smad2/3–positive cells in the thickened 
submesothelial compact zone compared with that in the control group (Figure 4A). 
Compared with that in the CG group, the number of positive cells was markedly reduced in 
the CG + SAHA group (Figure 4B, 4D). 265 
Next, we investigated the expression of TGF-xxb-dependent pro-fibrotic genes in the 
peritoneum tissue using real-time RT-PCR (Figure 4E – 4G). In the CG group, COLIxxa1, 
fibronectin and CTGF mRNA levels were higher than the control group. On the other hand, 
COLIxxa1, fibronectin and CTGF mRNA levels showed a tendency to be lower in the SAHA 
group.  270 
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SAHA INCREASED THE LEVEL OF HISTONE ACETYLATION 
Using immunofluorescence technique, we examined the level of H3K9 acetylation, which is 
representative of histone acetylation, in the cells of the submesothelial compact zone (Figure 
5). H3K9 acetylation was low in the cells of the peritoneum of the control group (Figure 5A). 275 
In the CG group, moderate H3K9 acetylation was observed in the thickened submesothelial 
compact zone. In contrast, in the CG + SAHA group, the level of H3K9 acetylation tended to 
be higher than that in the CG group (Figure 5B, 5C). 
SAHA INCREASED THE EXPRESSION OF BMP-7 
Next, we focused on BMP-7 as an inhibitory factor for fibrosis that is upregulated by the 280 
administration of HDACi (21). As shown in Figure 6, we examined the ratio of BMP-7–
positive cells to all submesothelial cells in the submesothelial compact zone. In the control 
group, a few BMP-7–positive cells were detected in the peritoneum (Figure 6A). Although in 
the CG group some BMP-7–positive cells were in the submesothelial compact zone, the ratio 
of BMP-7–positive cells was significantly increased in the CG + SAHA group compared 285 
with that in the CG group (Figure 6B – 6E). The BMP-7 mRNA level in the CG + SAHA 
group was significantly higher than levels in the CG group (Figure 6F).  
SAHA SUPPRESSED INFLAMMATION AND ANGIOGENESIS 
To examine anti-inflammatory and anti-angiogenic effects by SAHA in peritoneal tissues, we 
used immunohistochemistry for F4/80 and CD31, which are markers of macrophages or 290 
dendritic cells, and vessels respectively (Figure 7A – 7H). In the peritoneum of the CG + 
SAHA group, the numbers of both F4/80–positive cells and CD31–positive vessels were less 
than those of the CG group. We identified anti-inflammatory and anti-angiogenic effects of 
SAHA in models of peritoneal fibrosis.  
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DISCUSSION 295 
Our results indicated that SAHA effectively ameliorated peritoneal fibrosis. In addition, we 
confirmed that SAHA, as an HDAC inhibitor, promoted histone acetylation in the 
submesothelial compact zone of the peritoneum. Our study supports the existing data and 
reveals the beneficial effects of HDACi on fibrotic diseases. Previous studies described the 
effects of HDACi in various animal models, including heart failure (9), unilateral ureteral 300 
obstruction (8), and diabetic nephropathy (32). However, to our knowledge, this is the first 
study to investigate whether HDACi have inhibitory effects on peritoneal fibrosis. 
Because increased levels of histone acetylation are usually associated with transcriptional 
activation (20), we speculated that the promotion of histone acetylation could be an effective 
strategy for the suppression of peritoneal fibrosis. In the present study, we focused on the 305 
expression of BMP-7 among fibrosis inhibitory factors. It is an endogenous protein that 
belongs to the TGF-xxb superfamily and is known to prevent the development of fibrosis in 
various organs (33–35). BMP-7 has been suggested to suppress fibrosis by inhibiting TGF-
xxb1 synthesis (36) and by controlling TGF-xxb signaling via blocking the nuclear 
translocation of phosphorylated Smad2/3 (37). In fact, the association between BMP-7 and 310 
histone acetylation has been already shown (22). Marumo, et al. reported that marked 
induction of BMP-7 and the increase of strongly positive cells for acetylated histone were 
observed simultaneously in the proximal tubular cells during the recovery phase following 
renal ischemic reperfusion in mice (22). We also confirmed that the number of BMP-7–
positive cells increased in the submesothelial compact zone in the CG + SAHA group 315 
compared with that in the CG group, and our results suggested that BMP-7 is involved in the 
suppression of peritoneal fibrosis, where it inhibits TGF-xxb signaling. Although we do not 
yet understand the difference observed between the levels of BMP-7 mRNA and protein level 
Io K, et al., Page 15  
in the control group, this difference could have been caused by post-transcriptional regulation 
of protein synthesis, including mRNA stability and translational efficiency (38). 320 
In this study, the peritoneal samples from mice in the CG group had a marked thickening of 
the submesothelial compact zone and a heavy infiltration of various cells at day 21. The 
results of immunohistochemistry for F4/80, FSP-1 and xxaSMA suggested that a heavy 
infiltration of various cells in the peritoneum were mainly macrophages or dendritic cells, 
and myofibroblasts. The SAHA group had fewer inflammatory cells and myofibroblasts, in 325 
addition to displaying an inhibition of angiogenesis. Therefore, SAHA might have 
ameliorated peritoneal fibrosis by not only increasing the expression of BMP-7 but also 
inhibiting inflammation or angiogenesis.  
Our study has some limitations for clinical application. First, there are some differences 
between CG-induced peritoneal fibrosis and human peritoneal fibrosis. CG models induce a 330 
chemical irritant but the etiology of human EPS is more complicated (4). However, most of 
the histological changes in CG models are similar to peritoneal fibrosis in humans — 
injection of CG results in progression of fibrosis and thickening of the peritoneum similar to 
human peritoneal fibrosis. Second, we started the administration of SAHA and CG 
simultaneously; the effect of SAHA as a therapeutic intervention subsequent to starting CG is 335 
unknown. Therefore, we anticipate further investigation into the therapeutic effect of SAHA. 
Third, the dosage of SAHA used in our study was almost 3 times that used clinically in the 
treatment of human cutaneous T cell lymphoma. There were no side effects such as liver or 
kidney dysfunction and the increase in mortality between the CG + SAHA group and the 
control group in our investigation. The effective and safe dose of SAHA for mice may be 340 
different from that used for humans. Further studies are needed to clarify whether SAHA can 
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be used to reduce peritoneal fibrosis in PD patients and to examine the suitable dose of 
SAHA for humans.  
In conclusion, we have shown for the first time that SAHA inhibits the progression of 
peritoneal fibrosis in a mouse CG-induced peritoneal fibrosis model. Our result might be 345 
consistent with our hypothesis that SAHA inhibits the expression of fibrosis-associated 
factors via induction of BMP-7. Thus, SAHA represents a novel potential candidate for the 
treatment of peritoneal fibrosis. 
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FIGURE LEGENDS 
Figure 1 — The result of Masson's trichrome staining of peritoneal tissues. (A) In normal 470 
mice, the monolayer of mesothelial cells covered the entire surface of the peritoneum. (B) In 
the control group, peritoneal tissues were almost normal without thickening of the 
submesothelial zone. (C) The peritoneal tissues of the mice in the CG group showed marked 
thickening of the submesothelial compact zone and presence of numerous cells. (D) SAHA 
significantly prevented the progression of submesothelial thickening. (A–D), magnification 475 
200×; bars indicate the thickness of the submesothelial compact zone. (E) Bar graph showing 
the thickness of the submesothelial compact zone. Data are expressed as mean±SEM; * 
represents p<0.05. 
 
Figure 2 — The result of the immunohistochemical analysis for type III collagen. (A) In the 480 
control group, type III collagen expression in the submesothelial compact zone was 
equivalent to that of normal mice. (B) In the CG group, type III collagen was diffusely 
expressed in the submesothelial compact zone. (C) Type III collagen expression was clearly 
decreased in the CG+SAHA group. (D) The peritoneal tissue of CG+SAHA group was 
incubated with normal IgG instead of type III collagen antibody as a negative control. (A–D), 485 
magnification 200×; bars indicate the thickness of the submesothelial compact zone. (E) Bar 
graph showing the positive areas for type III collagen. Data are expressed as mean±SEM; * 
represents p<0.05. 
 
Figure 3 — The result of the immunohistochemical analysis for FSP-1 and xxaSMA. (A) The 490 
number of FSP-1–positive cells increased markedly in the CG group. (B) The expression of 
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FSP-1 was inhibited in the CG+SAHA group. (C) The peritoneal tissue of CG+SAHA group 
was incubated with normal IgG instead of FSP-1 antibody as a negative control. (A-C), 
magnification 200×; bars indicate the thickness of the submesothelial compact zone. (D) Bar 
graph showing the number of FSP-1–positive cells. Data are expressed as mean ± SEM; * 495 
represents p<0.05. (E) In the CG group, the number of xxaSMA–positive cells was increased. 
(F) The number of xxaSMA–positive cells was reduced in the CG+SAHA group. (G) The 
peritoneal tissue of CG+SAHA group was incubated with normal IgG instead of xxaSMA 
antibody as a negative control. (E–G), magnification 200×; bars indicate the thickness of the 
submesothelial compact zone. (H) Bar graph showing the number of xxaSMA–positive cells. 500 
Data are expressed as mean±SEM; * represents p<0.05. 
 
Figure 4 — The results of immunohistochemical analysis for phosphorylated Smad2/3 and 
TGF-b dependent profibrotic genes expression. 
(A) In the CG group, a number of phosphorylated-Smad2/3 positive cells were observed in 505 
thickened peritoneal compact zone. (B) These numbers were significantly decreased in the 
CG+SAHA group. (C) The peritoneal tissue of CG+SAHA group was incubated with normal 
IgG instead of phosphorylated Smad2/3 antibody as a negative control. (A–C), magnification 
200×; bars indicate the thickness of the submesothelial compact zone. (D) Bar graph showing 
the number of phosphorylated-Smad2/3–positive cells. Data are expressed as mean±SEM; * 510 
represents p<0.05. (E) COLIxxa1 expression levels were measured by quantitative RT-PCR 
relative to xxb-actin controls. Values are relative to the control group±SEM; * represents 
p<0.05. (F) Fibronectin expression levels were measured by quantitative RT-PCR relative to 
xxb-actin controls. Values are relative to the control group±SEM; * represents p<0.05. (G) 
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CTGF expression levels were measured by quantitative RT-PCR relative to xxb-actin 515 
controls. Values are relative to the control group±SEM; * represents p<0.05. 
 
Figure 5 — The result of the immunofluorescence staining for H3K9 acetylation. (A) The 
control group showed low level of H3K9 acetylation in the cells of the peritoneum. (B) In the 
CG group, moderate level of H3K9 acetylation was evident by the thickened submesothelial 520 
compact zone. (C) In the CG+SAHA group, the level of H3K9 acetylation tended to be 
higher than that in the CG group. (D) The peritoneal tissue of CG+SAHA group was 
incubated with normal IgG instead of H3K9 acetylation antibody as a negative control. (A–
D), magnification 200×; bars indicate the thickness of the submesothelial compact zone. 
 525 
Figure 6 — The result of the immunofluorescence staining for BMP-7. (A) In the control 
group, very few BMP-7–positive cells were shown in the peritoneum. (B) The CG group 
showed some BMP-7–positive cells in the submesothelial compact zone. (C) The BMP-7–
positive cells were increased in the CG+SAHA group. (D) The peritoneal tissue of 
CG+SAHA group was incubated with normal IgG instead of BMP-7 antibody as a negative 530 
control. (A–D), magnification 200×; bars indicate the thickness of the submesothelial 
compact zone. (E) Bar graph showing the BMP-7–positive cells. Data are expressed as 
mean±SEM; * represents p<0.05. (F) BMP-7 expression levels were measured by 
quantitative real-time RT-PCR relative to xxb-actin controls. Values are relative to the 
control group±SEM; * represents p<0.05. 535 
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Figure 7 — The result of the immunohistochemical analysis for F4/80 and CD31. (A) In the 
CG group, a number of F4/80–positive cells were observed in thickened peritoneal compact 
zone. (B) These numbers were significantly decreased in the CG+SAHA group. (C) The 
peritoneal tissue of CG+SAHA group was incubated with normal IgG instead of F4/80 540 
antibody as a negative control. (A–C), magnification 200×; bars indicate the thickness of the 
submesothelial compact zone. (D) Bar graph showing the number of F4/80–positive cells. 
Data are expressed as mean±SEM; * represents p<0.05. (E) The number of CD31–positive 
vessels increased markedly in the CG group. (F) The number of CD31–positive vessels was 
reduced in the CG+SAHA group. (G) The peritoneal tissue of CG+SAHA group was 545 
incubated with normal IgG instead of CD31 antibody as a negative control. (E-G), 
magnification 200×; bars indicate the thickness of the submesothelial compact zone. (H) Bar 
graph showing the number of CD31–positive vessels. Data are expressed as mean±SEM; * 
represents p<0.05. 
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